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Abstract
Introduction: Raltegravir is an HIV-1 integrase inhibitor currently used in treatment-experienced HIV-1-infected patients
resistant to other drug classes. In order to assess its central nervous system penetration, we measured raltegravir
concentrations in cerebrospinal fluid (CSF) and plasma in subjects receiving antiretroviral treatment regimens containing
this drug.
Methods: Raltegravir concentrations were determined by liquid chromatography tandem mass spectrometry in 25 paired
CSF and plasma samples from 16 HIV-1-infected individuals. The lower limit of quantitation was 2.0 ng/ml for CSF and
10 ng/ml for plasma.
Results: Twenty-four of the 25 CSF samples had detectable raltegravir concentrations with a median raltegravir
concentration of 18.4 ng/ml (range, ,2.0–126.0). The median plasma raltegravir concentration was 448 ng/ml (range, 37–
5180). CSF raltegravir concentrations correlated with CSF:plasma albumin ratios and CSF albumin concentrations.
Conclusions: Approximately 50% of the CSF specimens exceeded the IC95 levels reported to inhibit HIV-1 strains without
resistance to integrase inhibitors. In addition to contributing to control of systemic HIV-1 infection, raltegravir achieves local
inhibitory concentrations in CSF in most, but not all, patients. Blood-brain and blood-CSF barriers likely restrict drug entry,
while enhanced permeability of these barriers enhances drug entry.
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Introduction
Combination antiretroviral therapy (cART) has markedly
reduced the morbidity and mortality of HIV-1 infection,
transforming a generally lethal infection into a chronic disease
amenable to medical management [1]. Treatment has not only
reduced systemic disease, but also the various neurological
complications, including both central nervous system (CNS)
opportunistic infections and AIDS dementia complex (ADC)
associated with HIV-1 encephalitis (HIVE) [2]. These salutary
preventative and therapeutic effects on CNS diseases likely result
from systemic effects of therapy that maintain host defenses,
reduce immune activation and limit continuous re-seeding of the
brain [3]. However, more direct therapeutic effects on HIV-1
replication within the CNS may also be important in some patients
[4]. This latter effect requires that suppressive levels of drug reach
infected cells within the CNS to inhibit local virus propagation.
Raltegravir is the first HIV-1 integrase inhibitor to be licensed for
treatment, and is currently indicated for patients with resistance to
other classes of drugs [5]. It has been shown to potently reduce
plasma viremia without cross-resistance to other licensed drugs [6].
Its pharmacokinetics allows twice daily drug administration.
Raltegravir is approximately 83% bound to plasma proteins and
eliminated mainly by metabolism via uridine diphosphate glucur-
onosyltransferase (UGT) 1A1-mediated glucuronidation [7].
We undertook this study in order to assess the pharmacokinetics
of raltegravir in the cerebrospinal fluid (CSF) space. For an
antiretroviral drug to directly inhibit viral replication in the CNS, it
must be able to penetrate the blood-brain barrier (BBB) [8]. The
capacity of a drug to enter the CNS depends on a number of factors:
molecular size,lipophilicity,degree of ionization and plasma protein
binding, and whether or not the drug is a substrate for
transmembrane transporters such as multidrug resistance P-
glycoprotein (P-gp) [9]. While the CSF space is not synonymous
withthebrain extracellularenvironment,itisaconvenientsurrogate
tomeasuredrugpenetrationand antiviraleffectsacrossthe BBBand
blood-CSF barrier (BCB) [10]. We therefore measured raltegravir
concentrations in CSF and plasma in a series of subjects receiving
PLoS ONE | www.plosone.org 1 September 2009 | Volume 4 | Issue 9 | e6877this drug and undergoing lumbar punctures (LPs) in the context of
protocols examining other aspects of CNS HIV-1 infection.
Materials and Methods
Two groups of subjects at our two institutions who were
participating in studies involving LPs were included in the study:
subjects taking raltegravir as part of their therapeutic regimen for
resistant HIV-1 infection, and subjects participating in a treatment
intensification study adding raltegravir to their already-suppressive
(plasma HIV-1 RNA concentrations ,40 copies/ml) regimens.
Both groups received raltegravir at the recommended therapeutic
dosage (400 mg by mouth twice daily). Treatment adherence was
monitored only by diaries, pill counts and questioning of subjects,
but not by more direct methods. CSF and blood samples were
obtained under the auspices of research protocols approved by the
ethics committees of both sites, and all subjects gave their informed
consent. LPs were conducted in a standardised manner, and CSF
and plasma specimens were clarified by centrifugation and
immediately stored at 270uC until analysis.
Total raltegravir concentrations in plasma and CSF were
measured by liquid chromatography tandem mass spectrometry
(LC-MS/MS) using
13C-labeled raltegravir as the internal
standard. One hundred ml aliquots of plasma or CSF were treated
with acetonitrile to precipitate proteins and thereafter centrifuged
at 20,000 g. Ten ml of the supernatants were injected onto the high
performance liquid chromatography (HPLC) column
(5 cm62.1 mm Zorbax C-8, 5 mm column). Calibrators in
plasma (10 to 2400 ng/ml of raltegravir) and in CSF (2.0 to
100 ng/ml of raltegravir) were analyzed with all samples, along
with quality assurance controls at low, medium, and high
concentrations. The LC-MS/MS system used was an API 2000
(Applied Biosystems, Foster City, CA) triple-quadruple mass
spectrometer coupled to twin Micro-LC pumps and autosampler
(Perkin Elmer, Waltham, MA). The lower limit of quantitation
(LLQ) was 10 ng/ml for plasma and 2.0 ng/ml for CSF, with
coefficients of variation ranging from 3.6% to 6.95% for plasma
and 4.9% to 6.3% for CSF. Acceptance criteria for the
bioanalytical runs were in line with current Food and Drug
Administration (FDA) guidance on bioanalysis with respect to
accuracy and precision on calibrators and QA samples. CSF
values below the LLQ are presented as 1.0 ng/ml for descriptives.
HIV-1 RNA was quantified in CSF and plasma with COBAS
Amplicor HIV-1 Monitor Test, version 1.5 (Roche AB, Basel,
Switzerland) (Gothenburg samples) or Abbott RealTime HIV-1
(Abbott Molecular Inc, Des Plaines, IL) (San Francisco samples),
and run according to the manufacturers’ protocols. These assays
have lower detection limits of 20 copies/ml or less, and all values
below this are presented as 19 copies/ml (1.28 log10 copies/ml) for
descriptives. Blood CD4
+ T-cell count, CSF and blood albumin,
and CSF cell counts were performed in the local clinical
laboratories using standard methods. CSF:blood albumin ratios
(calculated as CSF albumin (ng/ml)/blood albumin (g/l)) were
used as an index of BBB/BCB disruption [11].
Nonparametric methods were used for group descriptives and
statistical correlations unless otherwise indicated. Pharmaco
kinetic estimates used area under the plasma or CSF concentration
versus time curve (AUC) to compare exposures in the two fluids.
These analyses used Prism 5 (Graphpad, San Diego, CA).
Results
Subjects
Ten resistant and six intensification subjects were included in the
study, providing a total of 25 visits with CSF and plasma
measurements of raltegravir: 15 from San Francisco (including all
in the intensification study) and 10 from Gothenburg (Table 1). All
Table 1. Subject Characteristics.
Resistant Intensification Total
number
Subjects 10 6 16
Sampling Visits 15 10 25
Male:Female 8:2 6:0 14:2
median (range) median (range) median (IQR)
Age 45 (22–63) 51 (48–62) 49 (44–55)
CD4 (610
6/l) 140 (0–490) 388 (198–819) 330 (137–436)
Plasma HIV RNA (log10 copies/ml) 2.23 (1.28–5.20) nd
CSF HIV RNA (log10 copies/ml) 1.28 (1.28–5.66) nd
CSF WBC (cells/ml) 4 (1–22) 2 (1–8) 3 (1–6)
CSF Albumin (mg/dl) 22.7 (17.4–54.9) 28.6 (15.3–39.0) 25.5 (18.5–33.3)
CSF:Plasma Albumin Ratio 5.66 (3.78–23.87) 6.21 (3.92–9.29) 5.93 (4.66–7.91)
Time on raltegravir (weeks) 10 (0.5–88) 8 (4–12) 10 (4–25)
Other Antiretroviral Medications
NRTIs 3 (0–3) 3 (2–3) 3 (2–3)
NNRTIs 0 (0–1) 0.5 (0–1) 0 (0–0.5)
PIs 1 (0–1) 1 (0–1) 1 (1–1)
EIs 0 (0–1) 0 (0–0) 0 (0–0)
Total 4 (1–4) 4 (3–5) 4 (3–4)
NRTIs and NNRTIs: nucleoside and non-nucleoside reverse transcriptase inhibitors; PIs: protease inhibitors; EIs: entry inhibitors.
doi:10.1371/journal.pone.0006877.t001
CSF Raltegravir
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in the two groups, but blood CD4 counts were lower in the resistant
group. Because the HIV-1 RNA measurements in the intensifica-
tion study will be run in batch after enrollment is completed, these
results are not yet available. CSF was generally non-inflammatory,
though eight subjects had elevated WBC counts (seven in the
treatment group with WBC counts between 6 and 22 cells/mla n d
one in the intensification group with 8 cells/ml). Group values of
both CSF albumin and the calculated CSF:plasma albumin ratios
were mildly elevated compared to published normal values
(albumin means for 41–50 year olds 20.4 mg/dl, SD 5.7 mg/dl
and for51–60 yearolds 24.2 mg/dl mean and 7.6 mg/dl SD;mean
albumin ratios 4.6 with SD of 1.3 for 41–50 year olds and 5.5 with
SD of 1.7 for 51–60 year olds [11]). The duration of raltegravir
treatment ranged from 4 days in one subject to 88 weeks, with an
overall median of 11 weeks of treatment. The most common
accompanying antiviral drugs included two nucleoside reverse
transcriptase inhibitors (NRTIs) and one protease inhibitor (PI).
Raltegravir concentrations
Figure 1 shows total CSF and plasma raltegravir concentrations
in relation to the time of sampling after the previous dose. Samples
were obtained at time points following dosing determined by the
parent study with two sample times extending beyond the 12 hour
dosing interval (median 7.8 hours, range 1.2–14 hours). All of the
plasma raltegravir concentrations were above the detection limit
(10 ng/ml) and the in vitro IC95 (drug concentration needed to
inhibit 95% of viral replication) levels from 9.0–15.0 ng/ml [7]
and ranged from 37 to 5180 ng/ml (median 448 ng/ml)
(Figure 1A). Twenty-four out of 25 CSF samples had detectable
raltegravir levels above the limit of detection (2.0 ng/ml) ranging
from 2.0 to 126 ng/ml (median 18.4 ng/ml) (Figure 1B). Thirteen
of the 25 CSF samples had raltegravir concentrations above
15.0 ng/ml, four were between the reported inhibitory concen-
trations of 9.0–15.0 ng/ml, and eight were below 9.0 ng/ml. The
CSF:plasma ratios for paired samples ranged from 0.01 to 0.61
(median 0.03) in those with detectable CSF raltegravir. The ratio
of the estimated CSF:plasma raltegravir AUCs over the dosing
interval was 0.03, the same as the median of the CSF:plasma ratios
of all the paired samples with measureable CSF raltegravir.
Relation to CSF albumin concentrations
We explored relationships between the CSF raltegravir concen-
trations and other measured variables, including the plasma
raltegravir concentrations, CSF albumin concentrations, the
CSF:plasma albumin ratios, CSF WBC counts and blood CD4+
T cells. Of these, only the related CSF albumin concentrations
(P=0.028, Spearman’s r=0.438) and CSF:blood albumin ratios
(P=0.008, Spearman’s r=0.517) were significant. In Figure 1B the
symbol size varies according to the subjects’ albumin ratios at the
time of sampling, allowing direct visualization of the CSF
concentrations in the context of the given albumin ratio ranges.
One of the subjects had three LPs during the course of her
illness and appears to illustrate the effect of altered BBB
permeability on CSF raltegravir levels (Figure 2). This patient
was 22 years old when she presented with multiple cerebral
Mycobacterium avium brain abscess. She had previously been treated
with several antiretroviral medications and her virus was
multiresistant. Hence, raltegravir was included in her regimen
which was started at diagnosis, along with treatment of her
mycobacterial infection with rifabutin, azithromycine and etham-
butol. She responded very well to these treatments. As shown in
Figure 2A, her initial CSF raltegravir was relatively high (105 ng/
ml), while the subsequent levels were lower (31.8 and 23.5 ng/ml).
This variation in drug concentrations did not correlate with
changes in plasma raltegravir levels (Figure 2B), despite all 3
samplings being taken at a similar, relatively late time in the dosing
interval (8.5–10 hours). By contrast, the pattern of reduction in the
high baseline CSF:plasma albumin ratio (Figure 2C) and CSF
albumin concentration (Figure 2D) paralleled the CSF raltegravir
concentration, suggesting that the lower CSF drug concentration
was related to restoration of the BBB/BCB as the patient
recovered clinically with reduction of plasma and CSF HIV-1
RNA levels (Figure 2E) and rapid increase in blood CD4+ T cells
(Figure 2F), along with overall clinical improvement.
Discussion
While detected in all but one subject, total (i.e. bound and
unbound) raltegravir CSF concentrations were considerably less
than those of plasma, overall estimated at about three percent.
Figure 1. Raltegravir concentrations in plasma (A) and CSF (B) in relation to the time after the previous dose. Results for individual
subject evaluations and repeat subject evaluations are indicated by the matching color of squares (plasma) and circles (CSF) coded for each subject.
A: The horizontal grey fill plots IC95 range of 9.0–15.0 ng/ml, while the lower dashed horizontal line within this zone shows the lower limit of
quantitation (LLQ) for plasma of 10.0 ng/ml. B: The one CSF measurement of raltegravir below the LLQ is plotted as if equal to 1.9 ng/ml (orange
circle). The size of the symbols in B. also varies with the CSF:albumin ratios at the time of sampling as shown by the grey circles in the key: the largest
circles show the one sample with ratio .10, the next largest the 5 samples for albumin ratios from 7.5–10, the next the 10 samples with ratios from 5–
7.4, and the smallest the 9 samples for ratios ,5. The dashed horizontal line within this zone shows the LLQ for CSF of 2.0 ng/ml.
doi:10.1371/journal.pone.0006877.g001
CSF Raltegravir
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previously described [12], they all were in the therapeutic range.
The CSF concentrations also varied, but were both above and
below in vitro estimates of inhibitory drug concentrations.
In individual cases it appeared that higher plasma raltegravir
concentrations were associated with higher CSF concentrations,
but this was not entirely consistent. Indeed, fully evaluating the
impact of different factors determining CSF exposure (plasma
concentration, time of sample collection following dose, BBB
dysfunction, concomitant drug administration, etc.) is complex
and will require a larger sample and more detailed modeling than
allowed by this relatively small study. Previous studies show that
plasma raltegravir levels vary, but display biphasic decay with a
terminal half-life of 7–12 hours, reach steady state within two
days, and achieve concentrations similar to those in this study [7].
Our observations suggest that CSF raltegravir concentrations are
also variable, and while plasma raltegravir and its decay kinetics
are likely important to achieving therapeutic CSF levels, other
factors also appear to be important.
In theory, it is the unbound fraction of an antiretroviral drug
that determines antiviral effect and it is also this fraction that is
available to traverse biological membranes and enter target tissue
compartments and cells. If one estimates the free concentration of
raltegravir in plasma in this study at 76 ng/ml (17% of the median
total concentration, 448 ng/ml), and if unbound raltegravir
diffused passively into the CSF in the absence of any active
Figure 2. Longitudinal data from patient with three samples over the course of her illness (see text). A: CSF raltegravir concentrations
fell as the patient recovered. B: Plasma raltegravir concentrations were variable despite similar times of sampling (shown in hours after dosing
adjacent to symbols). C: Decline in the albumin ratio with recovery. D: Similar decline in the CSF albumin concentrations. E: HIV-1 RNA treatment
response was parallel in plasma and CSF, with higher levels in the latter. F: Rapid blood CD4+ T cell recovery.
doi:10.1371/journal.pone.0006877.g002
CSF Raltegravir
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approximately equivalent to this unbound plasma level. However,
the median total CSF raltegravir levels were nearly 4–fold lower.
Even ignoring the lower binding in CSF, this suggests limited drug
entry or its active transport out of the CSF. Indeed, raltegravir has
previously been suggested to be a substrate for P-gp transport [13].
Correlation of CSF raltegravir concentrations with the albumin
ratios and CSF albumin concentrations, which provide measures
of BBB/BCB permeability, also suggests that these barriers are
active in restricting raltegravir entry. The illustrated case (Figure 2)
with three LPs during the course of her recovery from CNS
infection also presents anecdotal supporting evidence. As her
albumin ratio decreased from a very high value of 23.9, her CSF
raltegravir levels decreased in close parallel despite an increase in
plasma raltegravir on the third sampling. This case also
underscores the mixed interactions of raltegravir with the BBB
and albumin itself. On the one hand, the albumin ratio serves as
an indicator of the BBB disruption that likely enhances entry of
raltegravir. On the other hand, since albumin also binds
raltegravir, the free level of drug will also decrease proportionally
for a given total drug level as the albumin increases. Also, since
albumin levels in CSF are about 5 percent of those in blood, the
bound concentration in CSF is much lower than that in blood and
contributes less to the total measured drug. We did not directly
measure the unbound drug fraction in either plasma or CSF.
A salient question is whether the CSF raltegravir concentrations
are sufficient to directly inhibit local CNS HIV-1 replication. Here
again, one must consider the estimated free and bound raltegravir
in CSF, and the extracellular concentrations to achieve inhibition
of viral replication. Furthermore, treatment of HIVE that is
sustained in perivascular and parenchymal macrophages and
microglia relies on the drug concentration in brain extracellular
fluid surrounding these infected cells which may differ from CSF
concentration. Current estimates of inhibitory concentrations
depend largely on cell culture experiments using varying amounts
of human or fetal serum that bind raltegravir. Published values for
the IC95 are 15.0 ng/ml (33 nM) obtained in the presence of 50%
human serum and approximately 9.0 ng/ml (18.7 nM) measured
with 10% fetal bovine serum [7,14]; these are the figures used here
to estimate in vivo effectiveness. Although CSF is likely to bind less
of the drug, if one takes these values as spanning the lower range of
effectiveness, eight of the CSF samples in this study had lower
raltegravir levels (,9.0 ng/ml), four had levels between 9.0–
15.0 ng/ml, and thirteen had higher concentrations (Figure 1).
This suggests that raltegravir CSF exposure was likely inhibitory in
the CSF in more than half of the cases, exceeding or within the
spectrum of the IC95 of non-resistant virus. However, in some
patients CSF drug levels may well have been too low for this direct
suppressive activity.
In conclusion, raltegravir may directly contribute to treatment
of the autonomous component of CNS HIV-1 infection that is
sustained locally in some, but not all patients. Hence, its use in the
setting of ADC/HIVE or when direct CNS antiviral effect is
considered critical should be accompanied by careful individual
patient monitoring, including assessment of CSF HIV RNA
responses. Increases in BBB/BCB permeability associated with
HIVE [15] may actually favorably influence the treatment effect of
raltegravir in the setting of overt ADC as it seemed to in the
described patient. While we consider these results encouraging
with respect to inclusion of raltegravir in treatment regimens
targeting CNS infection, they also suggest the need for
accompanying CNS-penetrating drugs in this setting, and indicate
the need for more direct study of raltegravir CNS or CSF antiviral
effects to address this question. It is also important to emphasize
that antiviral drug impact on CNS infection involves other factors
that relate to their systemic effects, including preservation or
restoration of host defenses against HIV-1, control of immune
activation that contributes to CNS infection, and prevention of
continued seeding of the CNS [16].
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